Caris Life Sciences, Inc. Common Stock vs. CareDx, Inc.
Caris Life Sciences, Inc. Common Stock (CAI) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| CAI | CDNA | |
|---|---|---|
| Market Cap | $8.74 billion | $2.81 billion |
| Revenue (TTM) | $989.61 million | — |
| Net Income (TTM) | $105.14 million | — |
CAI leads on 1 of 1 size & scale factors.
Valuation
| CAI | CDNA | |
|---|---|---|
| P/E Ratio | 17.74 | — |
| Price / Book | 14.77 | — |
| Price / Sales | 8.83 | — |
CAI and CDNA split the valuation factors evenly.
Profitability
| CAI | CDNA | |
|---|---|---|
| Net Margin | 10.62% | — |
| Return on Equity | 17.77% | — |
CAI and CDNA split the profitability factors evenly.
Dividend
| CAI | CDNA | |
|---|---|---|
| Dividend Yield | 4.00% | — |
| Payout Ratio | 71.01 | — |
CAI and CDNA split the dividend factors evenly.
Risk & Sentiment
| CAI | CDNA | |
|---|---|---|
| Short Interest | 0.13% | 7.55% |
CAI leads on 1 of 1 risk & sentiment factors.
Dig deeper: CAI overview, CAI financials, CDNA overview, CDNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.